You are here:
Value of Information Case Study: Human Health and Economic Trade-offs Associated with the Timeliness, Uncertainty, and Costs of the Draft EPA Transcriptomic Assessment Product (ETAP)
Citation:
Devito, M., A. Harrill, R. Thomas, S. Hagiwara, D. Krewski, G. Paoli, P. Farrell, AND R. Sams. Value of Information Case Study: Human Health and Economic Trade-offs Associated with the Timeliness, Uncertainty, and Costs of the Draft EPA Transcriptomic Assessment Product (ETAP). U.S. Environmental Protection Agency, Washington, DC, EPA/600/X-23/082, 2024. https://doi.org/10.23645/epacomptox.26093572
Impact/Purpose:
N/A
Description:
Time is an important, but underappreciated component in chemical safety decisions. An estimated 15% of the chemicals in domestic commerce have traditional repeated dose toxicity testing data and even fewer have human health assessments that can be used to inform regulatory actions. The time and resources required to perform traditional toxicity testing and develop a human health assessment is substantial and, for many chemicals, human exposure continues to occur while toxicity data are collected, interpreted, and integrated into a human health reference value. Although new methods and approaches are increasingly available to more rapidly and cost effectively evaluate toxicity and develop human health assessments, there is hesitation to utilize newer approaches as compared with traditional paradigms. Objective approaches are needed to evaluate the potential trade-offs between timeliness of the toxicity testing and human health assessment, uncertainty of the information, and the associated costs and benefits of the testing and assessment approaches.
URLs/Downloads:
DOI: Value of Information Case Study: Human Health and Economic Trade-offs Associated with the Timeliness, Uncertainty, and Costs of the Draft EPA Transcriptomic Assessment Product (ETAP)
RECOMMENDATIONS AND DRAFT RESPONSES.PDF (PDF, NA pp, 184.929 KB, about PDF)
SUPPLEMENTAL MATERIAL.XLSX